Glaucoma is an eye condition that develops when the optic nerve, which serves as the main connection between the eye and the brain, becomes damaged. It occurs when the fluid in the eye does not properly drain out resulting in abnormal pressure inside the eye.
Glaucoma is a very common eye condition but in many cases, it is not promptly diagnosed. It sometimes takes a long time before it is detected, usually during a routine eye exam. Unfortunately, if left untreated, it can lead to vision loss.
Many patients do not have easy access to reliable glaucoma care in their own countries while those who have, such as those living in developed nations, find that treatment for their condition can set them back by thousands of dollars. This is the reason why medical tourism became popular and one of the best destinations for those who are looking for Western-quality care that is extremely affordable is Southeast Asia.
Southeast Asia is determined to become the leader in the global medical tourism industry, which explains its multi-million dollar investments in its hospitals and dedicated eye centres. Patients can find the very best in the region in Singapore, Thailand, and Malaysia, which are also home to highly skilled ophthalmologists that have been certified by international organisations.
Southeast Asia’s many well-trained eye experts and globally recognised hospitals and eye care centres offer innovative and breakthrough treatment options for glaucoma that use laser technology including trabeculoplasty, iridotomy, and cyclophotocoagulation.
Another option is microsurgery, which is not yet widely available in many countries because it requires special skills, instruments, and equipment. However, it can be taken advantage of by both local and international patients in Singapore, Thailand, and Malaysia. All glaucoma treatments are delivered using the same advanced technology and world-class medical facilities used in Western countries. However, they are significantly cheaper in Southeast Asia allowing patients to save up to 75% of the cost of the treatment in the United States or Europe.